Pds Biotechnology (PDSB)
NASDAQ:PDSB
Want to see PDSB full AI Analyst Report?
PDSB Stock Chart & Stats
$1.31
-$0.09(-5.36%)
At close: 4:00 PM EST
$1.31
-$0.09(-5.36%)
Day’s Range― - ―
52-Week Range$0.51 - $1.92
Previous CloseN/A
Volume197.50K
Average Volume (3M)1.06M
Market Cap
$64.75M
Enterprise Value$54.48M
Total Cash (Recent Filing)$21.66M
Total Debt (Recent Filing)$15.86M
Price to Earnings (P/E)―
Beta2.96
Next Earnings
Aug 18, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding55,815,655
10 Day Avg. Volume1,190,054
30 Day Avg. Volume1,064,804
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)3.86
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.94
Forecast
1Y Price Target
$7.50Price Target Upside472.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.55
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong IP And Unique Product ProfilePDS0101's differentiated dosing/formulation (subcutaneous, five doses) and newly granted U.S. and Japanese patents extending protection into the 2040s create durable product-market exclusivity. This structural advantage supports longer-term commercialization potential and partner interest if clinical endpoints are met.
Manufacturing And CMC ReadinessAn established Versamune manufacturing process and completed scale-up materially reduce late-stage regulatory and commercialization execution risk. Being CMC-ready shortens time from approval to launch, lowers tech-transfer hurdles for partners, and preserves margins long-term versus peers still resolving manufacturing scale.
Protocol Amendment De-risks TimelineAdopting PFS as an interim co-primary endpoint and cutting target enrollment materially shortens trial duration and cost, improving the chance of an accelerated approval pathway. This structural change increases the probability of an earlier regulatory milestone and lowers cash needs during pivotal development.
Bears Say
No Revenue; Persistent LossesThe company remains pre‑commercial with no material product revenue and consistent operating and free cash flow outflows. Over the medium term this means continued reliance on external capital to fund operations, constraining strategic flexibility and increasing execution risk if funding conditions tighten.
Balance-sheet FragilityA sharp increase in debt and very thin equity in 2025 produce an elevated debt-to-equity profile and fragile capitalization. Structurally, this heightens refinancing and covenant risk, may raise borrowing costs, and increases the likelihood of dilutive capital raises that can impair long-term investor returns.
Costly Financing And Dilution RiskRecent financing replaces secured convertible debentures with a high‑cost 10% note plus warrants and an ATM facility. While it addresses legacy secured debt, these structural terms raise ongoing interest expense and create meaningful dilution and conditional conversion mechanics that can erode equity value and strain future cash flow.
PDS Biotechnology News
PDSB FAQ
What was Pds Biotechnology’s price range in the past 12 months?
Pds Biotechnology lowest stock price was $0.51 and its highest was $1.92 in the past 12 months.
What is Pds Biotechnology’s market cap?
Pds Biotechnology’s market cap is $64.75M.
When is Pds Biotechnology’s upcoming earnings report date?
Pds Biotechnology’s upcoming earnings report date is Aug 18, 2026 which is in 75 days.
How were Pds Biotechnology’s earnings last quarter?
Pds Biotechnology released its earnings results on May 13, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.14 by $0.01.
Is Pds Biotechnology overvalued?
According to Wall Street analysts Pds Biotechnology’s price is currently Undervalued.
Does Pds Biotechnology pay dividends?
Pds Biotechnology does not currently pay dividends.
What is Pds Biotechnology’s EPS estimate?
Pds Biotechnology’s EPS estimate is -0.13.
How many shares outstanding does Pds Biotechnology have?
Pds Biotechnology has 55,815,655 shares outstanding.
What happened to Pds Biotechnology’s price movement after its last earnings report?
Pds Biotechnology reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.14. Following the earnings report the stock price went up 20.909%.
Which hedge fund is a major shareholder of Pds Biotechnology?
Currently, no hedge funds are holding shares in PDSB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PDS Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (472.52% Upside)
$7.50 (472.52% Upside)
Blogger Sentiment
Bullish
PDSB Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.41%
12-Months-Change
Fundamentals
Return on Equity
-346.03%
Trailing 12-Months
Asset Growth
-47.56%
Trailing 12-Months
Company Description
Pds Biotechnology
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
PDSB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical and intellectual property progress: a strategic protocol amendment for VERSATILE-003 that reduces patient count (~28.6%) and time to an interim readout, peer-reviewed and encouraging clinical data for PDS01ADC, strengthened IP extending PDS0101 protection into the 2040s, and established manufacturing processes. Financially, operating expenses and net loss improved year-over-year. Key risks include a relatively modest cash balance ($21.7M), continued unprofitability with rising interest expense, the need for OS data for full approval and additional confirmatory trials, and competition in the HPV16 head and neck space. On balance, the operational and clinical positives outweigh the near-term financial and development risks.View all PDSB earnings summariesPDSB Stock 12 Month Forecast
Average Price Target
$7.50
▲(472.52% Upside)
Technical Analysis
Ownership Overview
1.51%
Insiders
3.90% Mutual Funds
1.69% Other Institutional Investors
89.82% Public Companies and
Individual Investors